Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: An analysis of 3,258 patients in a single center

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Avilés, Agustin ^a   Jesus Nambo M ^b   Neri, Natividad ^b  

^a Oncology Research Oncology Diseases   (Mexico)

^b HOSPITAL DE ONCOLOGÍA   (Mexico)

Author keywords

Central nervous system prophylaxis; Central nervous system relapse; Malignant lymphoma; Prognostic factors

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; HYDROCORTISONE; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; FOLINIC ACID;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM PROPHYLAXIS; COMPARATIVE STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; CANCER CENTER; CENTRAL NERVOUS SYSTEM TUMOR; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER CARE FACILITIES; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; CYTARABINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCORTISONE; LEUCOVORIN; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; METHOTREXATE; MIDDLE AGED;

EID: 84874371590     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0520-0     Document Type: Article

References (30)

1. Siegal T, Goldschmid T. CNS prophylaxis in diffuse large B-cell lymphoma. If, when, how and for whom. Blood Rev. 2011;26:97-106.
2. McMillan A. Central nervous system direct preventive therapy in adults with lymphoma. Br J Haematol. 2005;131:13-21.
3. Franklin JC, Firlay J. Leukemia and lymphomas: treatment and prophylaxis of the central nervous system. Curr Treat Options Neurol. 2006;8:335-44.
4. Kridel R, Dietrich PY. Prevention of CNS relapse in diffuse large B-cell lymphoma. Lancet Oncol. 2011;12:1258-66.
5. Hill QA, Owen RG. CNS prophylaxis in lymphoma: who to target and therapy to use. Blood Rev. 2006;20:319-32.
6. Cheung CW, Burton C, Smith P, Lich DC, Hoskin PJ, Ardeshna KM. Central nervous system chemoprophylaxis in non-Hodgkin's lymphoma. Br J Haematol. 2005;131:193-200.
7. Bernstein SH, Unger JM, LeBlanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008;27:114-9.
8. Haioun C, Besson C, Lepage C, Thieblemont C, Simon D, Rose C, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis. Ann Oncol. 2000;11:685-90.
9. Shimazu Y, Notohara K, Veda Y. Diffuse large B-cell lymphoma with central nervous system relapse. Prognosis and risk factors according to retrospective analysis from an single-center experience. Int J Hematol. 2009;89:577-83.
10. Chihara D, Oki Y, Matsuo K, Onoda H, Taji H, Yamamoto K, et al. Incidence and risk-factors for central nervous system relapse in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2011;52:2270-5.
11. Boehme V, Zeynalova S, Kloess M, Loefler M, Kaiser U, Pfreudschuh M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma. A survey of 1,693 patients treated in protocols of the German High-grade non-Hodgkin's Lymphoma Study Group. Ann Oncol. 2007;18:149-57.
12. Kim SJ, Oh SY, Kim JS, Kim H, Lee GW, Won JH, et al. Secondary central nervous system involvement in patients with diffuse large B-cell lymphoma. Ann Hematol. 2011;90:539-46.
13. Bollem ELEM, Brouwer RE, Hamers S, Hermans J, Kluis M, Sankatsing RVA. Central nervous system non-Hodgkin's lymphoma. Arch Neurol. 1997;54:854-9.
14. Boehme V, Schimtz N, Zeynalova S, Loeffler M, Pfreudschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab. Blood. 2009;113:3896-902.
15. Hollender A, Kualoy S, Nome E, Skovlunde-Lote K, Holte H. Central nervous system involving following diagnosis of non-Hodgkin's lymphoma. Ann Oncol. 2002;13:1099-107.
16. Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP) regimen compared with standard CHOP for poor prognosis aggressive non-Hodgkin's lymphoma. Blood. 2003;102:4283-9.
17. Recher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma. Lancet. 2011;378:1858-67.
18. Abramson JS, Hellman M, Barnes JA, Hammerman P, Toomey C, Takuvian T, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low-risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010;116:4283-90.
19. Mitrovic Z, Bast M, Bierman PI, Bociek RG, Vose JM, Chan WC et al. The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma. Br j Haematol. 2012.
20. Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, et al. Incidence and risk for central nervous system recurrence in elderly patients with diffuse large B-cell lymphoma. Influence of rituximab. Ann Oncol. 2004;15:129-33.
21. Tai WM, Chune J, Tang PL, Koo YY, Hou X, Tay KW, et al. Central nervous system relapse in diffuse large B-cell lymphoma (DLBCL) Pre and post-rituximab. Ann Hematol. 2011;90:809-18.
22. Arkenau HT, Chont G, Cunningham D, Watkins D, Agarwai R, Sirohi B, et al. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol. 2007;18:541-8.
23. Avilés A, Castañeda C, Neri N, Cleto S, Nambo MJ. Rituximab and dose-dense therapy in primary breast lymphoma. Haematologica. 2007;92:1147-8.
24. Avilés A, Neri N, Huerta-Guzmán J, et al. Testicular lymphoma. Organ-specific treatment did not improve outcome. Oncology. 2004;67:211-4.
25. Avilés A, Fernández R, Pérez F, et al. Adjuvant radiotherapy in stage IV diffuse large B-cell lymphoma improve outcome. Leuk Lymphoma. 2004;45:385-9.
26. Hedge UL, Filie A, Little RF, Janik JE, Grant JN, Steinbergs M, et al. High-incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement. Blood. 2005;105:496-502.
27. Ahluwalid MS, Wallace PB, Peereboom DM. Flow-cytometry as a diagnostic tool in lymphomatous or leukemia meningitis. Cancer. 2012;118:1747-53.
28. Tanimoto T, Kusumi E, Hosuda K, et al. CNC prophylaxis in diffuse large B-cell lymphoma. Lancet. 2012;379:1485-6. (Letter).
29. Jabbour E, O'Brien S, Garcia-Manero G, Fernadoli A, Ravandi F, Cabanillas M, et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute leucemia. Blood. 2007;109:3214-8.
30. Perez-Larray JG, Palma JA, Carmona-Iragus M, Fernández-Torron R, Irimiz P, Rodríguez-Otero P, et al. Neurologic complications of intrathecal liposomal cytarabine administered prophylactically to patients with non-Hodgkin's lymphoma. J Neurooncol. 2011;103:603-9.